An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities (Q33274608)

25 July 2017

An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities (English)

1 reference

25 July 2017

0 references

2

Diego A Jaitin

1 reference

25 July 2017

Eyal Kalie

1

1 reference

25 July 2017

Renne Abramovich

series ordinal

3

1 reference

25 July 2017

Gideon Schreiber

series ordinal

4

1 reference

25 July 2017

language of work or name

English

0 references

publication date

19 February 2007

1 reference

Journal of Biological Chemistry

25 July 2017

1 reference

25 July 2017

282

1 reference

25 July 2017

15

1 reference

25 July 2017

11602-11611

1 reference

The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution

25 July 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Ligand-induced association of the type I interferon receptor components

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

How cells respond to interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

The interferon response circuit: induction and suppression by pathogenic viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Type I interferons (alpha/beta) in immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Mechanisms of type-I- and type-II-interferon-mediated signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Alpha-interferon and its effects on signalling pathways within cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Why do so many cancer patients fail to respond to interferon therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Phage display for selection of novel binding peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Biophysical analysis of the interaction of human ifnar2 expressed in E. coli with IFNalpha2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Fast transient cytokine-receptor interactions monitored in real time by reflectometric interference spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Insulin receptor: covalent labeling and identification of subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Mutational analysis of the IFNAR1 binding site on IFNalpha2 reveals the architecture of a weak ligand-receptor binding-site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Differential receptor subunit affinities of type I interferons govern differential signal activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

TRAIL is a key target in S-phase slowing-dependent apoptosis induced by interferon-beta in cervical carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Alternative signaling pathways regulating type I interferon-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

The type-I interferon receptor. The long and short of it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Interferon alpha-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Interferon-mediated anti-angiogenic therapy for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

Characterization of Antihuman IFNAR-1 Monoclonal Antibodies: Epitope Localization and Functional Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610115200

21 January 2018

Identifiers

DOI

10.1074/JBC.M610115200

1 reference

25 July 2017

1 reference